It’s Rare Disease Day 2019! In this blog post, Worldwide Clinical Trials employee Jackie Brusch talks about her uncommonly rare disorder, what she wants people to know about rare diseases, and how Worldwide is advancing rare disease clinical research.
Read More
Cardiovascular disease remains the number one killer of men and women in the U.S. While the need for new discovery is high, the reality is that little progress has been made to advance treatments during the past few decades – especially for one of the most serious conditions: heart failure.
Read More
Burden-of-illness real-world evidence studies – initiatives that establish the impact and overall cost of a particular disease from multiple perspectives – have always been important for drug developers, helping them to better understand how to optimally position a new product as a potential solution. That said, there are a number of reasons why it’s never been more critical to undertake burden-of-illness studies. Indeed, characterizing the burden of a particular disease should be viewed as an opportunity, rather than a burden.
Read More
The need for highly adaptive and innovative information technology permits data acquisition in diverse settings and can capture data from every physician/patient interaction occurring in the context of late phase clinical trials. Our latest blog explores this topic in detail.
Read More
Just a few years ago, “bundling” referred to drug/device combinations, but now we’re seeing fascinating pairings between drugs and innovative technologies, designed to optimize a drug’s success. Read more about our fourth prediction for real-world evidence in 2019.
Read More
At OCT West Coast 2019, Barbara Zupancic, Senior Director of Patient Recruitment and Retention, discussed the key factors that profoundly affect patient interest and eventually determine the success of a clinical trial, and we’re providing the highlights of her presentation in this blog.
Read More
